Brief: Appili Therapeutics Provides Enrollment Update For Its Phase 3 PRESECO Trial Evaluating Oral Antiviral Favipiravir As An Early Treatment In Covid-19

Appili Therapeutics

28/01/2021 11:21

Jan 28 (Reuters) - Appili Therapeutics Inc  APLI.TO :
    * APPILI THERAPEUTICS PROVIDES ENROLLMENT UPDATE FOR ITS
PHASE 3
PRESECO TRIAL EVALUATING THE ORAL ANTIVIRAL FAVIPIRAVIR AS AN
EARLY TREATMENT IN COVID-19
    * APPILI THERAPEUTICS INC - COMPANY IS PRIORITIZING
RESOURCES ON
PIVOTAL STUDY AND EXPECTS TO PROVIDE INTERIM DATA READOUT BY
LATE MARCH 2021
    * APPILI THERAPEUTICS - 12 SITES IN U.S. ACTIVELY RECRUITING
FOR
DOUBLE-BLIND PLACEBO-CONTROLLED STUDY IN MILD-TO-MODERATE
PATIENTS WITH COVID-19
    * APPILI THERAPEUTICS INC - PRESECO IS EVALUATING
FAVIPIRAVIR, AN
ORAL ANTIVIRAL, IN EARLY TREATMENT OF COVID-19 IN OUTPATIENT
SETTING
    * APPILI THERAPEUTICS INC - PURSUING REGULATORY APPROVALS TO
EXPAND PRESECO INTO SITES IN MEXICO, BRAZIL, AND COLOMBIA

Source text for Eikon:  ID:nBw6X6Ppma 
Further company coverage:  APLI.TO 

 ((Reuters.Briefs@thomsonreuters.com;))